Introduction

!
Barrett's esophagus may be complicated by dysplasia and esophageal adenocarcinoma. The relative incidence of esophageal adenocarcinoma has increased seven-fold over the past three decades [1, 2] . In the last decade, primary therapy of dysplastic Barrett's esophagus and early esophageal adenocarcinoma (EEA) has shifted from esophagectomy to endoscopic resection. Apart from lower morbidity and mortality compared with esophagectomy, endoscopic resection has significant diagnostic and therapeutic benefit [3, 4] . Focal endoscopic resection of visible abnormalities is recommended not only as a treatment of neoplastic Barrett's esophagus, but also as a tumor staging tool with inference to the risk of lymph node invasion. Because of the significant rates of metachronous dysplasia following focal endoscopic resection, elimination of the remaining Barrett's mucosa is advocated [5] . Options include radiofrequency ablation (RFA) and complete endoscopic resection (CER) by endoscopic mucosal resection or endoscopic submucosal dissection. CER provides comprehensive histological sampling with the advantage of definitively removing subtle synchronous EEA. CER is highly effective and safe in maintaining remission from cancer, dysplasia, and intestinal metaplasia [3] . The main limitation of endoscopic resection is the high risk of post-endoscopic resection esophageal stricture (PERES) formation, which is related to the horizontal and vertical extent of the resection (• " Fig. 1 ) [6, 7] . The reported rates of stricture formation post CER vary from 10 % to 88 % [6, 8] .
No effective therapy to prevent PERES has been described. Achieving CER of dysplastic Barrett's esophagus with minimal stricture formation is desirable. Safe, effective, easy-to-use, and costbeneficial prevention of PERES would significant- Background and aims: Complete endoscopic resection (CER) of short-segment Barrett's esophagus with high grade dysplasia (HGD) and early esophageal adenocarcinoma (EEA) is a precise staging tool and achieves durable disease control. The major drawback is development of postendoscopic resection esophageal stricture (PERES). No effective therapy to prevent PERES has been described. Viscous budesonide slurry (VBS) may have a role in the prevention of PERES by suppressing the post-CER inflammatory process. The study aim was to evaluate the efficacy of VBS for the prevention of PERES. Methods: Prospective data were collected on patients referred for CER of HGD or EEA. After January 2012, patients routinely received VBS (two 0.5-mg/2-mL budesonide respules mixed with sucralose) twice daily for 6 weeks following each stage of the CER schedule. All patients received high dose proton pump inhibitor therapy for the duration of CER and the following 3 months. Patients had no other intervention to prevent PERES. A validated dysphagia score was used (0 -4, no dysphagia to aphagia). Endoscopic dilation was performed for dysphagia. Patients receiving VBS were compared with historical controls. The primary endpoint was the need for dilation. Results: Between January 2008 and January 2015, 104 of 116 eligible patients completed CER. The VBS group (n = 29) and non-VBS group (n = 75) had similar patient, disease, and procedural characteristics. Dilations were needed in 13.8 % vs. 37.3 % (P = 0.03), with a median of one vs. two procedures (P = 0.01), and median dysphagia score during CER of 0 vs. 1 (P = 0.02) in the VBS and non-VBS groups, respectively. No VBS-related adverse events were noted. Conclusion: In this pilot study VBS significantly reduced PERES and shortened the dilation program after CER.
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ly enhance the acceptability of CER to patients and endoscopists. Whilst the pathophysiology of PERES is not well understood, the inflammatory state following endoscopic resection is thought to promote stricture formation. Viscous budesonide slurry (VBS) is beneficial for the treatment of eosinophilic esophagitis [9] and may have a role in PERES prevention through suppression of the post-CER inflammatory process. Topical steroid has been suggested as a potential treatment to prevent PERES but as yet no published data exist. We aimed to evaluate the efficacy of VBS for the prevention of PERES.
Methods
!
Data were collected as part of a prospective observational study of patients referred for endoscopic management of biopsy-proven high grade dysplasia (HGD) or EEA to a single tertiary-care referral center. Institutional review board approval was obtained (HREC/14/WMEAD/232).
Patients without significant comorbidities and with a Barrett's extent by Prague classification criteria of ≤ 3 cm in circumferential (C) length and ≤ 5 cm in maximal (M) length (≤ C3M5) were invited to undergo staged CER. A standardized CER protocol was used and has previously been described in detail [6] . The following groups of patients were excluded from the study: patients with substantial comorbidity and limited life-expectancy, Barrett's extent > C3 and/or > M5, submucosal carcinoma after focal ER, temporary esophageal stent insertion post-CER, and concurrent RFA. After January 2012, participants were routinely offered VBS. This was taken at 2 mg twice daily for 6 weeks after each stage of the CER schedule and for 3 months after completion. One of the study investigators demonstrated the preparation and use of VBS to consenting patients prior to commencement of CER. The slurry was made up by mixing two 0.5-mg/2-mL budesonide (Pulmicort; AstraZeneca, North Ryde, Australia) respules with five packets of sucralose (Splenda; Johnson & Johnson, Ultimo, Australia).
Between January 2008 and November 2011 patients did not receive budesonide or other interventions to prevent PERES. These patients were used as historical controls. All patients received high dose proton pump inhibitor (PPI) therapy for the duration of CER and for 3 months after completion. Endoscopic surveillance following CER was performed at intervals of 3 and 6 months, and then annually for up to 5 years. A validated dysphagia score was used (score 0, no swallowing problem; 1, difficulty with solids most of the time; 2, difficulty with semisolids most of the time; 3, difficulty with liquids most of the time; 4, aphagia) [10] . Endoscopic dilation was performed for dysphagia either as an unscheduled procedure or during booked endoscopy sessions (for CER or surveillance). The esophagus was dilated with Savary dilators in 1-mm increments by not more than 3 mm above the caliber at which resistance was first detected. Clinical data were obtained at endoscopic follow-up, by structured phone interviews 30 days after CER, and at the end of follow-up. The primary outcomes were the need for dilation and number of dilations. Secondary outcomes included adverse effects of VBS, and dysphagia score during CER and at the end of follow-up. The software program SPSS (Version 20.0; IBM Corp., Armonk, New York, USA) was used for statistical analysis. Two-tailed tests with a significance level of 5 % were used throughout. Chisquared or Fisher's exact tests were used as appropriate to test for association between categorical variables. Continuous variables were summarized using the mean, median, and interquartile range (IQR). The Mann-Whitney U test was used for comparison of quantitative variables with skewed distribution, while the t test was used for comparison of normally distributed quantitative variables. 
Results
!
Between January 2008 and January 2015, 116 of the 168 patients who were referred for endoscopic management of HGD or EEA met the inclusion criteria. Amongst the CER cohort, 29 patients took VBS and were compared with the 75 who did not. The flow of patients is summarized in• " Fig. 2 . The patient, lesion, and procedural characteristics were similar in both groups (• " Table 1 ).
Major intraprocedural bleeding and perforation was managed successfully during the procedure in all cases. One case of aspiration pneumonia occurred in the non-VBS group. The endpoints are summarized in• " Table 2 . Dilations were needed in 13.8 % compared with 37.3 % (P = 0.03), median procedures one vs. two (P = 0.01), in the VBS and non-VBS groups, respectively. The median dysphagia scores during CER were 0 and 1, respectively (P = 0.02). Self-reported complete VBS adherence was 27 out of 29 patients. Two patients did not adhere completely to the regimen because of nausea and taste disturbance. No adverse events were reported.
Discussion
! VBS holds promise as a treatment to prevent PERES from CER.
There was a significant reduction in the need for dilation, number of dilations, and dysphagia score during treatment in patients taking VBS compared with the historical controls who were not given VBS. The use of VBS was safe, well tolerated, and patients were compliant with therapy.
Complete elimination of Barrett's mucosa in patients with early neoplasia is recommended because of the high rates of metachronous dysplasia. CER as a comprehensive tissue-acquiring alternative offers diagnostic and therapeutic benefits that mirror the rationale for esophagectomy for early Barrett's neoplasia without the associated morbidity and mortality. The major limitation of CER is development of PERES, which is related to the surface area removed [6] . While it usually responds to endoscopic dilation, PERES may affect patients' nutrition, quality of life, and the acceptability of endoscopic therapy. Repeated dilations increase resource utilization and the risk of adverse effects. Therefore a safe, easy-to-use, and inexpensive intervention that 
VBS (n = 29)
No VBS (n = 75) P value effectively reduces PERES whilst enabling a comprehensive tissue-acquiring CER approach offers significant benefits. Several strategies to prevent PERES have been evaluated. These include the use of intralesional steroid injection, systemic corticosteroids, stent insertion, and tissue implantation [11 -13] . The majority of studies lack a control group or are based on animal models. Whilst studies testing steroid use appear to show some efficacy, most of the interventions have not been found to be of significant benefit. Furthermore, compared with the ease of use and low cost of VBS, most of the studied interventions are invasive and resource intensive. In a recent feasibility study, the early use of a fully covered self-expanding metal stent (SEMS) following single session CER did not prevent PERES and resulted in significant morbidity [14] . VBS appears to be effective in eosinophilic esophagitis because of suppression of the inflammatory response [9] . Although the pathophysiology of PERES is not well understood, an inflammatory process from thermal injury and wide mucosal ulceration is likely to initiate PERES. Because of its mode of delivery, the budesonide slurry achieves a long contact time and exposure to a considerable surface area in the esophagus [15] . VBS is an attractive treatment option because of its ease of use, low cost, and minimal systemic absorption. Its use in patients with eosinophilic esophagitis has been shown to be safe and well tolerated [9] . Our study had several limitations. These include lack of randomization, blinding, or placebo use; exclusion of Barrett's segments larger than C3 and/or M5; and a sample size that is insufficient to demonstrate a strong effect. Patient reporting of dysphagia score is subjective and may be biased if there is no placebo comparison. As the estimation of the degree of PERES is also subjective and inaccurate, we used dysphagia as the indication for dilation. We believe the use of this indication in both groups helps to limit potential bias.
Comparison of a cohort with historical controls has several methodological shortcomings. Because of the lack of randomization, there is potential for unknown confounders and/or bias in the threshold for dilation to favor our intervention. However, dilation was performed in a standardized manner for dysphagia in both groups. We included historical controls to provide a reference point of baseline stricture rates prior to our use of VBS. While these controls were matched in all aspects apart from receiving the intervention, they do not provide the methodological rigor of a prospective randomized controlled trial. In this first report of its application for PERES, we believe VBS clearly holds promise as a useful treatment to prevent this disorder. In conclusion, use of VBS is safe, well tolerated, and appears to reduce the need for, and number of, dilations in patients undergoing CER. This pilot experience provides grounds for further study and validation by a multicenter randomized controlled trial.
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